ATE459623T1 - Pyridoä2,3-düpyrimidine, die sich als hcv- inhibitoren eignen und verfahren zu deren herstellung - Google Patents

Pyridoä2,3-düpyrimidine, die sich als hcv- inhibitoren eignen und verfahren zu deren herstellung

Info

Publication number
ATE459623T1
ATE459623T1 AT06763142T AT06763142T ATE459623T1 AT E459623 T1 ATE459623 T1 AT E459623T1 AT 06763142 T AT06763142 T AT 06763142T AT 06763142 T AT06763142 T AT 06763142T AT E459623 T1 ATE459623 T1 AT E459623T1
Authority
AT
Austria
Prior art keywords
pyridoä2
düpyrimidines
production
hcv inhibitors
hcv
Prior art date
Application number
AT06763142T
Other languages
English (en)
Inventor
Kenneth Alan Simmen
Dominique Louis Nestor Ghislain Surleraux
Tse-I Lin
Oliver Lenz
Pierre Jean-Marie Bernard Raboisson
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Application granted granted Critical
Publication of ATE459623T1 publication Critical patent/ATE459623T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT06763142T 2005-05-12 2006-05-12 Pyridoä2,3-düpyrimidine, die sich als hcv- inhibitoren eignen und verfahren zu deren herstellung ATE459623T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US68040505P 2005-05-12 2005-05-12
EP05106214 2005-07-07
EP06075855 2006-04-06
PCT/EP2006/062290 WO2006120252A2 (en) 2005-05-12 2006-05-12 Pyrido[2,3-d]pyrimidines useful as hcv inhibitors, and methods for the preparation thereof

Publications (1)

Publication Number Publication Date
ATE459623T1 true ATE459623T1 (de) 2010-03-15

Family

ID=37198763

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06763142T ATE459623T1 (de) 2005-05-12 2006-05-12 Pyridoä2,3-düpyrimidine, die sich als hcv- inhibitoren eignen und verfahren zu deren herstellung

Country Status (20)

Country Link
US (1) US8022077B2 (de)
EP (1) EP1888580B1 (de)
JP (1) JP5464686B2 (de)
KR (1) KR20080007268A (de)
CN (1) CN101203515B (de)
AR (1) AR054122A1 (de)
AT (1) ATE459623T1 (de)
AU (1) AU2006245676B2 (de)
BR (1) BRPI0609098A2 (de)
CA (1) CA2608301C (de)
DE (1) DE602006012666D1 (de)
DK (1) DK1888580T3 (de)
ES (1) ES2341572T3 (de)
IL (1) IL186881A (de)
MX (1) MX2007014082A (de)
RU (1) RU2444522C2 (de)
SI (1) SI1888580T1 (de)
TW (1) TW200716631A (de)
WO (1) WO2006120252A2 (de)
ZA (1) ZA200709689B (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5046942B2 (ja) * 2004-09-30 2012-10-10 テイボテク・フアーマシユーチカルズ Ｈｃｖ阻害性の二環式ピリミジン類
AU2006226322B2 (en) * 2005-03-25 2012-03-29 Tibotec Pharmaceuticals Ltd. Heterobicylic inhibitors of HCV
AR056347A1 (es) 2005-05-12 2007-10-03 Tibotec Pharm Ltd Uso de compuestos de pteridina para fabricar medicamentos y composiciones farmaceuticas
ES2395386T3 (es) 2005-12-21 2013-02-12 Abbott Laboratories Compuestos antivirales
RU2441869C2 (ru) * 2005-12-21 2012-02-10 Эбботт Лэборетриз Противовирусные соединения
RU2467007C2 (ru) 2005-12-21 2012-11-20 Эбботт Лэборетриз Производные [1,8]нафтиридина, полезные в качестве ингибиторов репликации вируса hcv
RU2441010C2 (ru) * 2005-12-21 2012-01-27 Эбботт Лэборетриз Противовирусные соединения
CA2672737A1 (en) 2006-12-20 2008-11-06 Abbott Laboratories Anti-viral compounds
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
EP2376515A1 (de) 2008-12-23 2011-10-19 Pharmasset, Inc. Synthese von purinnukleosiden
CA2748057C (en) 2008-12-23 2018-07-03 Pharmasset, Inc. Nucleoside phosphoramidates
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
AU2011224558B2 (en) * 2010-03-10 2014-02-27 Abbvie Ireland Unlimited Company Solid compositions
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
CL2011000718A1 (es) 2010-03-31 2012-04-09 Gilead Pharmasset Llc Proceso para la preparacion de compuestos fosforados enantiomericos.
UY33312A (es) 2010-03-31 2011-10-31 Pharmasset Inc Fosforamidato de nucleosido de purina
PT3042910T (pt) 2010-11-30 2019-04-16 Gilead Pharmasset Llc 2'-espiro-nucleósidos para utilização na terapia da hepatite c
KR101946499B1 (ko) 2011-04-08 2019-02-11 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염 치료를 위한 피리미딘 유도체
EP2776439B1 (de) 2011-11-09 2018-07-04 Janssen Sciences Ireland UC Purinderivate zur behandlung von virusinfektionen
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
CA2874800C (en) 2012-07-13 2021-04-06 Janssen R&D Ireland Macrocyclic purines for the treatment of viral infections
NZ705589A (en) 2012-10-10 2019-05-31 Janssen Sciences Ireland Uc Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
AU2013346793B2 (en) 2012-11-16 2018-03-08 Janssen Sciences Ireland Uc Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
KR102225233B1 (ko) 2013-02-21 2021-03-09 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염의 치료를 위한 2-아미노피리미딘 유도체
MX366481B (es) 2013-03-29 2019-07-09 Janssen Sciences Ireland Uc Deaza-purinonas macrociclicas para el tratamiento de infecciones virales.
MY188071A (en) 2013-05-24 2021-11-16 Janssen Sciences Ireland Uc Pyridone derivatives for the treatment of viral infections and further diseases
CN109369643B (zh) 2013-06-27 2021-05-18 爱尔兰詹森科学公司 用于治疗病毒感染和其他疾病的吡咯并[3,2-d]嘧啶衍生物
EP3027624B1 (de) 2013-07-30 2018-09-12 Janssen Sciences Ireland UC Thieno[3,2-d]pyrimidin-derivate zur behandlung von virusinfektionen
EP3650014B1 (de) 2013-08-27 2021-10-06 Gilead Pharmasset LLC Kombinationsformulierung von zwei antiviralen verbindungen
HUE050761T2 (hu) 2014-01-01 2021-01-28 Medivation Tech Llc Vegyületek és alkalmazási eljárások
EP2905024A1 (de) 2014-02-07 2015-08-12 Institut Quimic De Sarriá Cets, Fundació Privada Pyrido[2,3-d]pyrimidin-7(8H)-on-Derivate zur Behandlung von Flaviviridae Infectionen
WO2018002319A1 (en) 2016-07-01 2018-01-04 Janssen Sciences Ireland Uc Dihydropyranopyrimidines for the treatment of viral infections
WO2018060317A1 (en) 2016-09-29 2018-04-05 Janssen Sciences Ireland Uc Pyrimidine prodrugs for the treatment of viral infections and further diseases
TW202415645A (zh) 2018-03-01 2024-04-16 愛爾蘭商健生科學愛爾蘭無限公司 ２，４－二胺基喹唑啉衍生物及其醫學用途
WO2024243025A1 (en) * 2023-05-19 2024-11-28 Ikena Oncology, Inc. Naphthyl-substituted pyrido[4,3-d]pyrimidines and related compounds and their use in treating medical conditions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE789496A (de) * 1971-10-05 1973-03-29 S M B Anciens Ets J Muelberger
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
CA2472619A1 (en) 2002-01-10 2003-07-24 Bayer Corporation Fused pyrimidine derivates as rho-kinase inhibitors
JP2003321472A (ja) 2002-02-26 2003-11-11 Takeda Chem Ind Ltd Ｇｒｋ阻害剤
EP1511738A4 (de) * 2002-05-17 2007-05-09 Scios Inc Behandlung von fibroproliferativen erkrankungen unter einsatz von tgf-beta-inhibitoren
AU2003260072A1 (en) 2002-08-27 2004-03-19 Bristol-Myers Squibb Company Antagonists of chemokine receptors
US7148226B2 (en) * 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
WO2005032481A2 (en) * 2003-09-30 2005-04-14 Scios Inc. Quinazoline derivatives as medicaments
ES2369282T3 (es) * 2005-03-25 2011-11-29 Tibotec Pharmaceuticals Inhibidores heterobicíclicos de vhc.
AU2006226322B2 (en) * 2005-03-25 2012-03-29 Tibotec Pharmaceuticals Ltd. Heterobicylic inhibitors of HCV

Also Published As

Publication number Publication date
KR20080007268A (ko) 2008-01-17
IL186881A (en) 2015-06-30
EP1888580A2 (de) 2008-02-20
ZA200709689B (en) 2009-07-29
DK1888580T3 (da) 2010-06-14
AR054122A1 (es) 2007-06-06
ES2341572T3 (es) 2010-06-22
CA2608301A1 (en) 2006-11-16
DE602006012666D1 (de) 2010-04-15
RU2007146173A (ru) 2009-06-20
CN101203515A (zh) 2008-06-18
EP1888580B1 (de) 2010-03-03
US20090131460A1 (en) 2009-05-21
IL186881A0 (en) 2008-02-09
AU2006245676B2 (en) 2012-08-02
BRPI0609098A2 (pt) 2010-02-17
SI1888580T1 (sl) 2010-06-30
MX2007014082A (es) 2008-04-17
RU2444522C2 (ru) 2012-03-10
WO2006120252A2 (en) 2006-11-16
CN101203515B (zh) 2014-02-26
WO2006120252A3 (en) 2007-02-22
CA2608301C (en) 2014-04-22
AU2006245676A1 (en) 2006-11-16
US8022077B2 (en) 2011-09-20
TW200716631A (en) 2007-05-01
JP2008540494A (ja) 2008-11-20
JP5464686B2 (ja) 2014-04-09

Similar Documents

Publication Publication Date Title
ATE459623T1 (de) Pyridoä2,3-düpyrimidine, die sich als hcv- inhibitoren eignen und verfahren zu deren herstellung
ATE554772T1 (de) Pteridine als hcv-hemmer und verfahren zu ihrer herstellung
DE602006007336D1 (de) Umspritzte behälter und verfahren zu deren herstellung
ATE556077T1 (de) Tetrahydrochinolinderivate und verfahren zu deren herstellung
EP1921674A4 (de) Halbleiterbauelement und verfahren zu seiner herstellung
ATE419260T1 (de) C-aryl-glucosid-sglt2-inhibitoren und verfahren zu ihrer herstellung
EP1894626A4 (de) Homogener, hochdisperser metallkatalysator und verfahren zu seiner herstellung
DE602006020386D1 (de) Duraimplantat und Verfahren zu seiner Herstellung
DE602004021927D1 (de) Halbleiterbauelement und verfahren zu seiner herstellung
DE602006012283D1 (de) Integrierte schaltung und verfahren zu ihrer herstellung
EP1800317A4 (de) Isolatorbeschichtung und verfahren zu ihrer herstellung
DE602005024051D1 (de) Sorptionswärmeaustauschmodul und verfahren zu dessen herstellung
DE602005007419D1 (de) Rohmix-pulverzusammensetzungen und verfahren zu deren herstellung
EP1743174A4 (de) Multimodale nanostrukturen, verfahren zu deren herstellung und verwendung
DE602004014588D1 (de) Kupferlegierung und Verfahren zu deren Herstellung
DE602005013692D1 (de) Halbleiterbauelement und verfahren zu seiner herstellung
ATE423166T1 (de) Pflanzliches-öl-stärkepfropfcopolymere und ihre biofaserverbundwerkstoffe und verfahren zu ihrer herstellung
DE602005020902D1 (de) Kurbel für fahrrad und verfahren zu deren herstellung
DE112006000438A5 (de) Verschleissverbesserte Kette sowie Verfahren zu deren Herstellung
ATE482193T1 (de) Indolonacetamidderivate, verfahren zu deren herstellung und deren verwendungen
DE602004008991D1 (de) Umlenkbeschlag und verfahren zu dessen herstellung
EP1906468A4 (de) Batteriedose und verfahren zu ihrer herstellung
ATE535510T1 (de) Benzylamine, verfahren zu ihrer herstellung und ihre verwendung als entzündungshemmende mittel
DE502006003563D1 (de) Polyester-polysiloxan-copolymere und verfahren zu deren herstellung
DE602004009841D1 (de) Diffusionsplatte und Verfahren zu deren Herstellung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties